Akebia Therapeutics Misses Q4 Earnings Estimates

The biopharmaceutical company reported a loss of $0.05 per share, falling short of the $0.03 loss expected by analysts.

Feb. 26, 2026 at 9:34pm

Got story updates? Submit your updates here. ›

Akebia Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease treatments, announced its fourth quarter earnings results on Thursday. The company reported a loss of $0.05 per share, missing the consensus estimate of a $0.03 loss per share. Akebia's revenue for the quarter was $57.62 million, exceeding the expected $48.37 million.

Why it matters

As a clinical-stage biotech, Akebia's financial performance and pipeline progress are closely watched by investors. The earnings miss, despite higher-than-expected revenue, suggests the company is facing challenges in controlling costs as it advances its lead drug candidate vadadustat through late-stage trials for anemia associated with chronic kidney disease.

The details

Akebia reported a net loss of $0.05 per share for the fourth quarter, falling short of the $0.03 loss per share expected by analysts. However, the company's revenue of $57.62 million exceeded the consensus estimate of $48.37 million. Akebia's lead drug candidate vadadustat is currently in late-stage clinical trials for the treatment of anemia in chronic kidney disease patients.

  • Akebia announced its Q4 earnings results on Thursday, February 26, 2026.
  • The company's stock traded up $0.11 to $1.32 per share on the day of the earnings announcement.

The players

Akebia Therapeutics

A clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for patients with kidney disease, headquartered in Cambridge, Massachusetts.

vadadustat

Akebia's lead drug candidate, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease.

Got photos? Submit your photos here. ›

The takeaway

Akebia Therapeutics' Q4 earnings miss highlights the challenges facing clinical-stage biotech companies as they work to advance their drug pipelines. The company will need to closely manage costs while continuing to make progress with its lead candidate vadadustat in order to deliver value for shareholders.